Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The price of Rigel Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Rigel Pharmaceutical Inc. | - | - | - | - |
iShares Core DAX® | -5.585% | -6.284% | 8.869% | 8.070% |
iShares Nasdaq 100 | -7.241% | -13.117% | 18.200% | 28.955% |
iShares Nikkei 225® | -8.933% | -10.904% | 2.614% | -1.478% |
iShares S&P 500 | -6.148% | -7.562% | 17.896% | 31.811% |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)